inflectra
What will Pfizer do with its second Remicade biosimilar?
December 14, 2017Sales and Marketing Ixifi, Johnson & Johnson, Pfizer, Remicade, biosimilars, biotech, drugs, inflectra, pharma, pharmaceutical
Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these …
Switching Crohn’s patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says
October 30, 2017Research and Development, Sales and Marketing Crohn’s disease, Pfizer, Remicade, crohn's disease, inflectra, pharma
Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to …
Pfizer’s Remicade biosimilar displays similar efficacy
February 22, 2017Research and Development Johnson & Johnson, Pfizer, Remicade, inflectra
Pfizer and Celltrion have announced new data for their Remicade biosimilar, Inflectra, that shows that the drug is comparable in …
Pfizer sets release date for rival to J&J’s blockbuster drug
October 18, 2016Manufacturing and Production J&J, JJ, Johnson & Johnson, Pfizer, Remicade, inflectra
Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. …
Data supports switching to Hospira biosimilar for RA
June 10, 2015Research and Development, Sales and Marketing EULAR, Hospira, Janssen, RA, brett wells, celltrion, inflectra, rome
Findings presented at EULAR this week from the first real-world study in patients with rheumatic diseases supports switching from J&J’s …
Hospira launches biosimilar monoclonal antibody
February 16, 2015Research and Development, Sales and Marketing MSD, Merck, Remicade, biosimilar. hospira, inflectra, infliximab
Hospira has won the race to become the first company to launch a biosimilar version of an anti-TNF biologic, after …
Hospira’s Inflectra approved in Europe
September 10, 2013Research and Development, Sales and Marketing Hospira, Janssen, Remicade, biosimilars, inflectra
Hospira has been the first firm to meet the European Commission’s approval for a biosimilar monoclonal antibody therapy with its …
